Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval
by Zacks Equity Research
Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.
Intercept Starts OCA Trial for NASH Patients With Cirrhosis
by Zacks Equity Research
Intercept (ICPT) initiates a randomized phase III trial, REVERSE, on obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis.
Shire (SHPG) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Shire (SHPG) will report its Q4 results on Feb 14, 2018.
Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?
by Zacks Equity Research
Growth in Jakafi sales are likely to help Incyte (INCY) to beat on earnings in Q4.
Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings?
by Zacks Equity Research
The recent weakness in lead drug Ocaliva sales due to safety issues may mar Intercept's (ICPT) performance in the fourth quarter.
FDA Okays J&J's Prostate Cancer Drug in First-Line Setting
by Zacks Equity Research
The FDA lends a nod to the label expansion of Johnson & Johnson's (JNJ) Zytiga in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer.
Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
by Zacks Equity Research
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investors' focus will remain on the company's pipeline on fourth-quarter earnings call.
Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2017.
Zoetis (ZTS) Warming Up to Q4 Earnings: What's in Store?
by Zacks Equity Research
Zoetis (ZTS) is working on returning value to shareholders in the form of share buybacks and dividends.
Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Although Prothena's (PRTA) track record is good, the company is unlikely to beat estimates in the current quarter given the unfavorable rank and Earnings ESP.
Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow
by Zacks Equity Research
Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.
Theravance, J&J Ink Deal for Inflammatory Intestinal Drug
by Zacks Equity Research
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4
by Zacks Equity Research
Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.
Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down
by Zacks Equity Research
Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.
Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural
by Zacks Equity Research
Zacks.com featured highlights include: Lululemon, Exelixis, IDEXX, Teradyne and Pioneer Natural
5 Biotech Stocks Set to Trump Estimates This Earnings Season
by Zacks Equity Research
Total earnings for the medical sector are up 16.9% from the same period last year on 8.5% higher revenues so far.
Bristol-Myers' Opdivo/Yervoy Combo Positive in Cancer Study
by Zacks Equity Research
Bristol-Myers' (BMY) blockbuster drug, Opdivo, in combination with Yervoy, proves its worth again by demonstrating superiority in a lung cancer study.
Spectrum Pharma's Rolontis Positive in Pivotal Cancer Study
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) Rolontis meets primary endpoint in a phase III study for management of neutropenia in early stage breast cancer.
Pfizer Files for Xtandi in Early Stage Prostate Cancer
by Zacks Equity Research
Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.
Roche Reports Positive Data From Tecentriq-Avastin Study
by Zacks Equity Research
Roche reported positive results from a phase III study on the combination of immunotherapy drug Tecentriq and oncology drug Avastin.
5 of the Best Efficient Stocks for Your Portfolio
by Tirthankar Chakraborty
Companies with a favorable efficiency level are expected to provide impressive returns as efficiency is believed to be positively correlated with price performance.
Is a Beat in the Cards for ImmunoGen (IMGN) in Q4 Earnings?
by Zacks Equity Research
ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q4.
Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?
by Zacks Equity Research
Keryx (KERX) will provide updates on lead drug Auryxia when it reports Q4 results on Feb 7.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion's (ALXN) Q4 results are likely to driven by Soliris' performance.
Strength Seen in Alkermes (ALKS): Stock Soars 8.7%
by Zacks Equity Research
Alkermes (ALKS) was a big mover last session, as the company saw its shares rise more than 8% on Friday amid huge volumes.